Cost-efficacy of oral triptans in the treatment of acute migraine

References

• Ferrari MD. Migraine. Lancet 1998; 351: 1043–1051.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. New England Journal of Medicine 2002; 346: 257–270.
   PubMed Web of Science ®Google Scholar
• Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors, and co-morbidities. Neurology 2001; 56: S4–12.
   Google Scholar
• Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999; 53: 537–542.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996; 47: 52–59.
   PubMed Web of Science ®Google Scholar
• van Roijen L, Essink-Bot ML, Koopmanschap MA et al. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995; 7: 170–179.
   PubMed Web of Science ®Google Scholar
• Pascual J, Leira R, Lainez JM et al. [Spanish study of quality of life in migraine (II). Profile of medication consumption and subjective efficacy.] Neurologia 1999; 14: 204–209.
   Google Scholar
• Winner P, Ricalde O, Le Force B, Saper J et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Archives of Neurology 1996; 53: 180–184.
   PubMed Web of Science ®Google Scholar
• Touchon J, Bertin L, Pilgrim AJ et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361–365.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25–30.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–1287.
   PubMed Web of Science ®Google Scholar
• García-del-Pozo J, Carvajal A, Grajal C et al. Antimigraine drug consumption in Spain (1990–2000). Acta Neurologica Scandinavica 2003; 107: 158–160.
   PubMedGoogle Scholar
• Center for Clinical Health Policy Research. Evidence report: New 5-HT1 Agonists (Triptans). Durham, NC: Duke University, 1998.
   Google Scholar
• Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Canadian Journal of Neurological Sciences 2001; 28: 30–41.
   PubMed Web of Science ®Google Scholar
• Dahlof CG, Dodick D, Dowson AJ et al. How does almotriptan compare with other triptans? A review of data from placebo- controlled clinical trials. Headache 2002; 42: 99–113.
   PubMed Web of Science ®Google Scholar
• Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002; 42: 93–98.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–1675.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633–658
   PubMed Web of Science ®Google Scholar
• Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. American Journal of Managed Care 2002; 8: S80–S84.
   Web of Science ®Google Scholar
• Gracia-Naya M. [Cost effectiveness of treatment with triptans in Spain.] Revista de Neurologia 2001; 33: 921–924.
   Google Scholar
• Belsey JD. The clinical and financial impact of oral triptans – an updated meta-analysis. Journal of Medical Economics 2002; 5: 79–89.
   Google Scholar
• Mannix LK, Adelman JU, Goldfarb SD et al. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. American Journal of Managed Care 2002; 8: S94–S101.
   Web of Science ®Google Scholar
• Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002; 42 (Suppl 1): 38–43.
   PubMedGoogle Scholar
• Wang JT, Barr CE, Torigoe Y et al. Cost savings in migraine associated with less chest pain on new triptan therapy. American Journal of Managed Care 2002; 8: S102–S107.
   Web of Science ®Google Scholar
• IMS Health Therapy Area Sales Report. 2002. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 (Suppl 7): 1–96.
   Google Scholar
• Ferrari M. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 19 (Suppl 23): 2–4; discussion 4–8.
   Google Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 2002; 42 (Suppl 1): 20–26.
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. [Catalog of Medicinal Products.] Madrid, Spain: Consejo General de Colegios Oficiales de Farmacéuticos, 2002.
   Google Scholar
• SOIKOS. [Database of Healthcare Costs.] Barcelona, Spain: Centro de Estudios en Economía de Salud y Política Social, 2002.
   Google Scholar
• Mark DH. Visualizing cost-effectiveness analysis. JAMA: The Journal of the American Medical Association 2002; 287: 2428–2429.
   PubMedGoogle Scholar
• Cady RC, Ryan R, Jhingran P et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Archives of Internal Medicine 1998; 158: 1013–1018.
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Carides GW, Gerth WC et al. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000; 20: 830–834.
   PubMed Web of Science ®Google Scholar
• Meddis D, Sawyer JPC. Health economic outcomes in migraine: impact of zolmitriptan. Rev Contemp Pharmacother 2000; 11: 133–138.
   Google Scholar
• Lofland JH, Kim SS, Batenhorst AS et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clinic Proceedings 2001; 76: 1093–1101.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Sharfman M, Johnson R et al. Impact of oral sumatriptan on work-place productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. American Journal of Managed Care 1996; 2: 1407–1416.
   Google Scholar
• Anon MC. The economic burden of migraine. The role of triptans. American Journal of Managed Care 1998; 4 (Suppl 10): S630–S632.
   Google Scholar
• Anon MC. Triptan use and the economic impact of migraine. American Journal of Managed Care 1998; 4 (Suppl 10): S633– S636.
   Google Scholar
• Láinez MJ, Leira R, Liaño H et al. Effect on productivity and quality of life of oral sumatriptan. Headache 2000; 40: 415.
   Google Scholar
• Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000; 18: 557–566.
   PubMed Web of Science ®Google Scholar
• Kozma CM, Mauch RP, Reeder CE et al. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clinical Therapeutics 1994; 16: 1037–1051.
   PubMedGoogle Scholar
• Kozma CM, Reeder CE. Comparison of the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clinical Therapeutics 1995; 17: 315–319.
   PubMedGoogle Scholar
• Payne K, Kozma CM, Lawrence BJ. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost- efficacy analysis. Pharmacoeconomics 1996; 10: 59–71.
   PubMedGoogle Scholar
• Coukell AJ, Lamb HM. Sumatriptan. A pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997; 11: 473– 490.
   PubMed Web of Science ®Google Scholar
• Evans KW, Boan JA, Evans JL et al. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997; 12: 565–577.
   PubMed Web of Science ®Google Scholar
• Ottervanger JP, Valkenburg HA, Grobbee DE et al. Characteristics and determinants of sumatriptan-associated chest pain. Archives of Neurology 1997; 54: 1387–1392.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Reekers M, Bax WA et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25–30.
   PubMed Web of Science ®Google Scholar
• Young WB, Mannix L, Adelman JU et al. Cardiac risk factors and the use of triptans: a survey study. Headache 2000; 40: 587–591.
   PubMed Web of Science ®Google Scholar
• Welch KM, Mathew NT, Stone P et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687–695.
   PubMed Web of Science ®Google Scholar